Pfizer's new drug candidate, which targets the Borrelia bacteria, has shown promising results in a clinical trial. The drug is being developed as a collaboration between the pharmaceutical company and the Russian Federation. It is believed that there are as many as 476,000 cases of the disease each year. The vaccine candidate works by targeting the outer surface proteins of the bacteria, helping the body create antibodies to them.